Raimondi, L.; Raimondi, F.M.; Pietranera, M.; Di Rocco, A.; Di Benedetto, L.; Miele, E.; Lazzeroni, R.; Cimino, G.; Spinelli, G.P.
Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors. Cancers 2021, 13, 1928.
https://doi.org/10.3390/cancers13081928
AMA Style
Raimondi L, Raimondi FM, Pietranera M, Di Rocco A, Di Benedetto L, Miele E, Lazzeroni R, Cimino G, Spinelli GP.
Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors. Cancers. 2021; 13(8):1928.
https://doi.org/10.3390/cancers13081928
Chicago/Turabian Style
Raimondi, Lucrezia, Filippo Maria Raimondi, Marta Pietranera, Arianna Di Rocco, Laura Di Benedetto, Evelina Miele, Rachele Lazzeroni, Giuseppe Cimino, and Gian Paolo Spinelli.
2021. "Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors" Cancers 13, no. 8: 1928.
https://doi.org/10.3390/cancers13081928
APA Style
Raimondi, L., Raimondi, F. M., Pietranera, M., Di Rocco, A., Di Benedetto, L., Miele, E., Lazzeroni, R., Cimino, G., & Spinelli, G. P.
(2021). Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors. Cancers, 13(8), 1928.
https://doi.org/10.3390/cancers13081928
